Valuation: Larimar Therapeutics, Inc.

Market Cap 221M 197M 182M 165M 311M 20.97B 316M 2.19B 860M 10.97B 830M 813M 34.99B P/E 2026 *
-1.59x
P/E 2027 * -1.8x
Enterprise Value 134M 119M 110M 99.85M 188M 12.66B 191M 1.32B 519M 6.62B 501M 491M 21.13B EV / Sales 2026 *
-
EV / Sales 2027 * 5.3x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day+15.09%
1 week-3.56%
Current month-23.63%
1 month-35.62%
3 months-34.05%
6 months-49.17%
Current year-35.96%
1 week 1.92
Extreme 1.915
2.49
1 month 1.92
Extreme 1.915
3.96
Current year 1.92
Extreme 1.915
6.42
1 year 1.92
Extreme 1.915
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
13.68
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 01/05/2020
President 50 29/09/2026
Director of Finance/CFO 67 28/05/2020
Director TitleAgeSince
Director/Board Member 67 01/01/2020
Chairman 61 28/05/2020
Director/Board Member 58 28/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 A Free

Chairperson

850,000 0.9931%
7/6/26 A Buy

Director

50,000 0.0584%
5/19/26 A Free

Director

55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
+15.09%-3.56%-41.90%-14.69% 221M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +4.30%-1.16%+43.42%+107.50% 37.6B
Weighted average by Cap. +3.06%+0.61%+51.64%+122.64%

Financials

2026 *2027 *
Net sales - 41.74M 37.15M 34.42M 31.2M 58.69M 3.96B 59.58M 412M 162M 2.07B 157M 153M 6.6B
Net income -137M -122M -113M -102M -193M -12.99B -196M -1.35B -532M -6.79B -514M -503M -21.67B -155M -138M -128M -116M -218M -14.7B -221M -1.53B -602M -7.69B -582M -570M -24.52B
Net Debt -87.7M -78.06M -72.32M -65.55M -123M -8.31B -125M -867M -341M -4.35B -329M -322M -13.87B -
Projected Income Statement - Annual - Larimar Therapeutics, Inc.
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
20/10/26 $2.450 +15.57% 1,792,248
19/10/26 $2.120 +6.80% 1,231,361
16/10/26 $1.985 -0.25% 1,691,973
15/10/26 $1.990 -4.78% 6,179,736
14/10/26 $2.090 -3.24% 2,257,468
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Larimar Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.450USD
Average target price
14.40USD
Spread / Average Target
+487.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Larimar Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. LRMR Stock